Login
Navigate Fool.com
Will ENMD beat
the market?

ENTREMED, INC.

NASDAQ: ENMD

Community Rating: Unrated

1.87 -0.05 (-2.60%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.89
Previous Close $1.92
Daily Range $1.85 - $1.90
52-Week Range $1.45 - $2.38
Market Cap $50.6M
P/E Ratio -8.50
Dividend (Yield) $0.00 (0.0%)
Volume 11,742
Average Daily Volume 24,311
Current FY EPS $0.00

How do you think ENMD
will perform against the market?

Top ENMD Bull/Bear Pitches

 

ShuntSD (< 20)
Submitted October 20, 2006

As others say, a gamble with huge upside. But the small molecule research is promising and acquisition was a nice move. Keep close eye on it with stops.

0 Replies Reply Report this Post
 

hlacheen (< 20)
Submitted December 22, 2006

Just look at the income statement and cash flow.... this company is a cash-burning disaster, it is NOT worth $120m

0 Replies Reply Report this Post

News & Commentary

Why We Love Wild Penny Stocks

It's not what you think. We swear.

Sector Update: Healthcare Shares Flat Pre-Market; Sangamo Drops 2% on Pricing Public Offering

Sector Update: Healthcare

Sector Update: Healthcare Shares Flat Pre-Market; Cell Therapeutics Dips 2% on Results of Lymphoma D

Sector Update: Healthcare Shares Flat Pre-Market; Cell Therapeutics Dips 2% on Results of Lymphoma Drug Study

Sector Update: Healthcare

New Stock Coverage: Ameriprise Turns Tommy Lee Jones Into Fat Cat

24/7 Wall St. Closing Bell — November 26, 2012: Markets Open Low, Closed Mixed (MCD, YHOO, FB, BHP,

24/7 Wall St. Closing Bell — November 26, 2012: Markets Open Low, Closed Mixed (MCD, YHOO, FB, BHP, DE, ADT, RAH, KCG, MMR, ENMD)

Stock Downgrades: Bank of Ireland Struggles to Stay in Green

Wall Street ratings agencies set the tone for today's stock market.

10 Biotechs Targeting Cancer Stem Cell Destruction

Here, a partial list of emerging public companies with programs that take a novel approach to eradicating cancer.

EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress

See More ENMD News...

Sector

Healthcare

Industry

Drugs

ENTREMED, INC. (ENMD) Description

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. Website: http://www.entremed.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks